SEMMELWEIS EGYETEM

Their core work

Semmelweis University is Hungary's leading medical university, deeply engaged in clinical research spanning mental health, cardiovascular disease, immunology, and personalized medicine. Their H2020 portfolio shows strong capabilities in clinical trials, complement system biology, mRNA therapeutics, and AI-driven diagnostics. They contribute patient cohorts, clinical expertise, and translational research capacity to large European health consortia, bridging the gap between laboratory discoveries and bedside applications across Central and Eastern Europe.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Semmelweis focused on molecular medicine infrastructure building (HU-MOLMEDEX, HCEMM), cardiovascular clinical trials (SECURE), and foundational biomedical research including cancer glycobiology and extracellular vesicles. From 2019 onward, the focus shifted decisively toward mental health (depression, anxiety, compulsivity appear repeatedly), AI-powered clinical tools, mRNA therapeutics, and complement diagnostics — with Semmelweis also stepping into coordination roles for the first time. This evolution reflects a transition from broad participation in established biomedical areas to more targeted leadership in psychiatric research, digital health, and advanced therapeutics.

Semmelweis is converging mental health research with digital health and AI tools, positioning itself as a strong partner for precision psychiatry and AI-assisted clinical decision-making in European consortia.

How they like to work

Semmelweis operates almost exclusively as a consortium partner (27 of 31 projects), contributing clinical expertise and patient access rather than leading project design. With 421 unique partners across 42 countries, they maintain an exceptionally broad network, suggesting they are a sought-after clinical partner rather than a repeat-collaborator with a narrow circle. Their two coordinator roles came only in 2020 (Biosafety, AmReSu), both under Widening Participation calls — indicating growing ambition to lead, particularly in CEE capacity-building contexts.

With 421 unique consortium partners across 42 countries, Semmelweis has one of the broadest collaboration networks among Hungarian institutions. Their partnerships span Western European research hospitals, CEE molecular medicine centers, and pan-European health data initiatives.

What sets them apart

Semmelweis is Hungary's premier medical university and the strongest Hungarian player in EU health research, with 31 H2020 projects covering an unusually wide clinical spectrum from psychiatry to immunology to mRNA therapeutics. Their dual strength in mental health research and complement biology is rare — few institutions combine deep psychiatric cohort access with advanced immunology. For consortium builders, they offer a reliable CEE clinical partner with established patient recruitment infrastructure and growing digital health capabilities.

Highlights from their portfolio

• EXPERT
  Largest single grant (EUR 687K) — working on mRNA therapeutic platforms with lipid nanoparticles, directly relevant to post-COVID therapeutic manufacturing.
• Biosafety
  One of only two projects Semmelweis coordinated — develops complement diagnostic assays, showcasing their leadership in immunology diagnostics.
• BIGPICTURE
  Part of one of Europe's largest digital pathology AI initiatives, building a central repository — signals Semmelweis's commitment to AI in clinical medicine.